Emma Walmsley To Step Down As GSK CEO After Nine Years, Luke Miels To Lead Starting January 2026

Group 1 - GSK plc appointed Luke Miels as CEO Designate, effective January 1, 2026, succeeding Dame Emma Walmsley [1][3] - Miels has been with GSK since 2017 as Chief Commercial Officer, focusing on medicines and vaccines, particularly in oncology and respiratory [1][2] - GSK aims for total sales exceeding £40 billion ($53.76 billion) by 2031, marking 2026 as a pivotal year for growth [2][3] Group 2 - Walmsley will step down on December 31, 2025, but will assist the new CEO until September 30, 2026, particularly regarding geopolitical impacts and new technologies [3][4] - Under Walmsley's leadership since 2017, GSK has spun off Haleon plc and shifted focus to oncology and infectious diseases to counteract patent losses and revenue declines by 2030 [5] - GSK's stock rose by 2.36% to $40.80 during premarket trading [5]